Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005
Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals
You may also be interested in...
Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.
Ocera went public by completing a reverse merger with the failing biotech Tranzyme, then completed a $20 million PIPE financing that positions it to begin a Phase IIb trial studying its lead drug for a rare liver disease.
Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies